Literature DB >> 26400457

Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia.

Daniel L Youssef1, Pradeep Narayanan2, Neeraj Gill3.   

Abstract

OBJECTIVE: To determine the incidence of clozapine-induced myocarditis and cardiomyopathy and identify risk factors.
METHOD: A cohort of 129 patients initiated on clozapine at Toowoomba Mental Health Service from year 2000 until 2011 was examined to evaluate cases of myocarditis and cardiomyopathy. Risk factors were analysed using multivariable logistic regression.
RESULTS: The incidence of clozapine-induced myocarditis and cardiomyopathy was 3.88% and 4.65% (or 2.26 per 100 patient years), respectively. A significant association was identified between clozapine-induced myocarditis and SSRI use (p = 0.043). Subclinical cardiomyopathy was identified in the absence of symptoms in the majority of cases.
CONCLUSIONS: These results illustrate a high incidence of clozapine-induced myocarditis as well as cardiomyopathy, reinforcing the need for a standardised, mandatory monitoring scheme. Concomitant SSRI use as one such potential predictor merits further study. © The Royal Australian and New Zealand College of Psychiatrists 2015.

Entities:  

Keywords:  cardiomyopathy; clozapine; incidence; myocarditis; risk factors

Mesh:

Substances:

Year:  2015        PMID: 26400457     DOI: 10.1177/1039856215604480

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  13 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Clozapine-Induced Cardiomyopathy in Parkinson's Disease.

Authors:  Unax Lertxundi; Rafael Hernández; Juan Medrano; Saioa Domingo-Echaburu; Montserrat García; Carmelo Aguirre
Journal:  Mov Disord Clin Pract       Date:  2017-03-11

3.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 4.  Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.

Authors:  Kathlyn J Ronaldson
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 5.  Systematic Review of Clozapine Cardiotoxicity.

Authors:  Martina Curto; Nicoletta Girardi; Luana Lionetto; Giuseppino M Ciavarella; Stefano Ferracuti; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-07       Impact factor: 5.285

6.  Incidence and Management of Clozapine-Induced Myocarditis in a Large Tertiary Hospital.

Authors:  Julia M Higgins; Cindy San; Gillian Lagnado; Doson Chua; Tamara Mihic
Journal:  Can J Psychiatry       Date:  2019-01-01       Impact factor: 4.356

7.  Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition.

Authors:  Bryan K Sackey; Troy A Moore; Nicole L Cupples; Cynthia A Gutierrez
Journal:  Ment Health Clin       Date:  2018-11-01

8.  Left Ventricular Thrombus as a Complication of Clozapine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.

Authors:  Shahbaz A Malik; Sarah Malik; Taylor F Dowsley; Balwinder Singh
Journal:  Case Rep Cardiol       Date:  2015-11-18

9.  Clozapine-induced hypertension: A case report and review of literature.

Authors:  Sandeep Grover; Swapnajeet Sahoo; Sonali Mahajan
Journal:  Ind Psychiatry J       Date:  2017 Jan-Jun

Review 10.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.